A Follow-Up on the “Tale of Two Wounds” and the Madness of Skin Substitute Pricing
Summary: Dr. Caroline Fife reflects on two patient cases to highlight dramatic disparities in cost for skin substitutes (“skin subs”) used in wound care—billing differences that yield huge expenses for Medicare/taxpayers and high out-of-pocket burdens for patients. The post questions why pricing for minimally manipulated amniotic skin products varies by more than 1000%, and raises concerns about unnecessary use driven by profit rather than clinical need.
Key Highlights:
- Case comparison: Wound #1 cost nearly **$500,000** (payer + taxpayer), with patient responsible for ~$99,760; Wound #2, treated with presumably similar products/wounds, cost < 1% of that sum, with patient cost ~$900.
- Dr. Fife highlights that in Wound #1, PT and NP providers reportedly made ~$124,700 each by splitting discounted pricing from the distributor—underscoring financial incentive concerns.
- The post points out that many amniotic skin substitutes are labelled “minimally manipulated,” yet pricing per cm² can differ over **1000%** across products—raising questions over fairness, value, and regulatory oversight.
- Upcoming reimbursement changes by CMS may help moderate costs, but the author is skeptical about how much lobbyists and market forces will allow that to happen.
Read the full editorial on CarolineFifeMD.com
Keywords:
skin substitute pricing,
amniotic products,
Medicare reimbursement,
financial incentives,
Caroline Fife